GlaxoSmithKline Pharmaceuticals Stock: Valuation and P/E
GLAXO.NSGlaxoSmithKline Pharmaceuticals trades at a P/E of 40.3 (Drug Manufacturers (General) median 17.3, own median of recent years 50.8). It was last lower at the fiscal 2026 year end (37.3).
Daily figure as of 22 Nov 2026
P/E on Expected Earnings
The forward P/E of 35.2 divides the price by the earnings per share that 4 analysts expect on average for the next twelve months: $0.84. The twelve months are made up pro rata of the estimates for fiscal 2027 and 2028.
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against Its Own Valuation History
Each fiscal year is shown with its P/E on the year-end date, using the price at the time. From 2017 to 2026 the P/E at fiscal year end ranged from 16.7 (2022) to 228.6 (2020).
P/E at Each Fiscal Year End
Figures as a table
| Year | P/E |
|---|---|
| 2017 | 69 |
| 2018 | 50.8 |
| 2019 | 49.4 |
| 2020 | 228.6 |
| 2021 | 68.2 |
| 2022 | 16.7 |
| 2023 | 36.9 |
| 2024 | 57 |
| 2025 | 51.1 |
| 2026 | 37.3 |
P/E of Industry Peers
| Stock | P/E | Own median |
|---|---|---|
| Daiichi Sankyo | 17.8 | 38.4 |
| Orion | 21.5 | 22.2 |
| Zhangzhou Pientzehuang Pharmaceutical. | 58.9 | 49.8 |
| CSPC Pharmaceutical Group | 10.5 | 20.6 |
| Grifols | 15.2 | 30.5 |
| Ono Pharmaceutical | 15.5 | 19.0 |
| GlaxoSmithKline Pharmaceuticals | 40.3 | 50.8 |
| Organon | 17.8 | 5.7 |
| Virbac | 18.4 | 25.0 |
The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 22 Nov 2026, loss makers have none.
Earnings Yield and Interest Rates
Put the other way round, earnings per share over the last twelve months equal 2.5% of the share price. That is the earnings yield. Ten-year government bonds of the home country (India) yielded 6.9% on average over the last five years, the same rate the fair value uses. So the earnings yield is 4.4 percentage points lower. Unlike interest, earnings are not guaranteed. They fluctuate and can disappear.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
